Project Bolero is a Florida-based 503A sterile compounding pharmacy, licensed in 33 states, that Diatonic Healthcare has agreed to acquire for $242M. Compounding pharmacies prepare customized medications to a physician’s prescription for individual patients. Bolero focuses on the hardest segment of that work: 86% of its revenue comes from sterile injectables made under USP <797> standards, which only about 16% of Florida pharmacies can produce. Its product mix includes peptides, hormone replacement therapy (HRT), GLP-1s and other specialty drugs. It serves more than 150,000 patients through more than 1,200 prescribers, all acquired organically, with 85% retention.
With the midterms pointing toward divided government for the rest of the Trump term, that profile puts Bolero in a strong position, for four reasons.
The upside is coming through executive action, which a divided Congress can’t easily undo.
The key catalyst for Bolero is peptide access, and it is moving through the FDA rather than Congress. On October 14, 2026, the FDA submitted an “Interim Access Policy for Compounding Using Certain Peptides” to the Office of Management and Budget for review. People familiar with the plan say it would let compounding pharmacies temporarily produce some of the most sought-after peptides, including BPC-157, without facing enforcement. BPC-157 is Bolero’s #1 product. A Democratic House could hold hearings on this. Reversing it by law, however, would require both chambers and a presidential signature. Gridlock therefore tends to protect agency policy that is already in motion.1,2
Gridlock tends to protect agency policy that is already in motion.
The administration’s commitment is explicit.
Kennedy has expressed support for compounding peptides. He said this week that the administration aims to expand access by creating a regulated marketplace, so that what patients get is what it claims to be, safe and from inspected facilities. The midterms don’t change who runs HHS or the FDA. Bolero’s regulatory sponsor stays in place at least through January 2029.3,4
Being cash-pay keeps Bolero out of the main healthcare fights in Congress.
Bolero’s patients pay directly, so it has no insurance, payer or PBM exposure. A divided Congress will spend its healthcare energy on reimbursement: ACA subsidies, Medicaid, PBM reform and drug price negotiation. Most of what it might legislate on healthcare simply doesn’t touch Bolero’s revenue.
Affordability politics favors lower-cost alternatives.
The lead-up to the elections was marked by an inflation surge, and polling showed it was voters’ top issue. A Congress elected on affordability is more likely to pressure branded drug pricing than to restrict lower-cost, physician-directed alternatives. Bolero’s 2024 summary judgment win against Novo Nordisk shows it can defend that position in court.5
The counterarguments investors should weigh
The interim policy is not yet law and is easy to reverse. Legal compounding remains prohibited unless the FDA accepts the recommendations and completes proposed and final rulemaking. An interim enforcement-discretion policy is easier to reverse than a final rule, and the 2028 presidential election falls inside Bolero’s four-year hold.6
A Democratic House would bring oversight, possibly with teeth. The process has drawn sharp criticism. The advisory panel’s support was narrow and overrode FDA career scientists, who had recommended against all seven peptides. Health policy commentators have argued that listing these peptides could greatly expand patient exposure without consistent quality standards or FDA safety oversight. A Democratic House could hold hearings, issue subpoenas, or attach appropriations riders that limit FDA enforcement discretion.6,7
Forecasts are not results. The House looks likely to change hands, but the Senate is much closer and could go either way.
Sources
- 1. Holland & Knight (hklaw.com)
- 2. American Tribune
- 3. National Community Pharmacists Association (NCPA)
- 4. GV Wire
- 5. Wikipedia
- 6. The American Journal of Managed Care (AJMC)
- 7. Health Affairs
For information only; not an offer to sell or a solicitation of an offer to buy any security, and not investment advice.
Back to Insights